Drug Profile
HYAL AT2101
Alternative Names: Diclofenac + HA topical; Hyaluronic acid + diclofenac; Hyanalgese-D; OraleaseLatest Information Update: 11 Dec 2007
Price :
$50
*
At a glance
- Originator SkyePharma Inc
- Developer Pacira Pharmaceuticals; SkyePharma Inc; Symbion Health
- Class Glycosaminoglycans; Nonsteroidal anti-inflammatories; Phenylacetates
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Aphthous ulcer pain; Pain; Rheumatic disorders
Most Recent Events
- 08 Dec 1998 Phase-III clinical trials for Aphthous ulcer pain in USA (Topical)
- 01 Oct 1998 Hyal Pharmaceutical has acquired the rights to HYAL AT2101 in Asian countries, which had been licensed to its Australian subsidiary
- 12 Feb 1998 Discontinued-III for Pain in Austria (Topical)